Genflow Biosciences Share Discussion Threads

[bri15] 29/1/2024 12:20

I really think we at bottom now,well I bloody hope so as I just put more in 😁

[bri15] 29/1/2024 12:14

Since the rise that is.

[bri15] 29/1/2024 12:09

N14 it's more than ridiculous when you think it's only about £20K total sells which have wiped about £1.3 million off the market cap.

[northeast14] 29/1/2024 11:53

Ridiculous seeing us back down here. Our cash in bank and grants money is bigger than mcap now.

[bri15] 29/1/2024 11:50

Nearly back to pre grant awards price,so very over sold territory now.

[bri15] 29/1/2024 11:32

Getting annoyed with the constant drop,I losing hefty chunk here now 😡

[moneymunch] 29/1/2024 07:04

Genflow Biosciences PLC (LSE:GENF, OTCQB:GENFF) chief executive officer Dr. Eric Leire spoke with Proactive's Stephen Gunnion to discuss the impact of two substantial research grants awarded to Genflow in Belgium.

These grants are not just financial boons but are fostering critical collaborations in the field of advanced therapy medicinal products (ATMPs), marking a new era in biotechnological research and development.

Stephen Gunnion (SG): Dr. Leire, can you elaborate on the scope of these grants and their importance for Genflow Biosciences?

Eric Leire (EL): These grants are a major milestone for us. They primarily focus on enhancing collaborations in advanced therapy medicinal products, or ATMPs. Specifically, they support our partnerships with EXO Biologics for exosome manufacturing and Revatis SA for sarcopenia research. Sarcopenia, the age-related muscle loss condition, is a critical research area for Genflow. The grants cover 80% of the project costs, which is substantial financial backing, allowing us to enhance our research capabilities significantly.

SG: Could you shed some light on how these collaborations align with Genflow’s broader strategic goals?

EL: Absolutely. These collaborations are integral to our three-year plan of building a robust biotech ecosystem in Belgium. By working closely with academic centres and various biotech actors, we aim to significantly bolster our research capabilities. This not only enhances our company valuation through meaningful milestones but also strengthens our position in the biotech market by increasing shareholder value and validating the scientific rigour of our research.

SG: With such a focused approach towards ATMPs and age-related diseases, what are the long-term implications for Genflow's research portfolio?

EL: Our long-term vision is to expand our pipeline, focusing on gene therapy and age-related diseases. This strategy is designed to mitigate financial and scientific risks in the challenging biotech market. By diversifying and strengthening our research portfolio, we aim to establish Genflow as a leader in biotech innovation, particularly in the field of longevity and age-related conditions.

SG: Finally, what are the future plans for Genflow in terms of collaborations and research directions?

EL: Looking ahead, we are actively seeking further collaborations to expand our pipeline. While we remain dedicated to gene therapy and tackling age-related diseases, our goal is to create a diversified research portfolio that can withstand market challenges. This approach is essential for sustainable growth and continued innovation in biotechnology.

[northeast14] 28/1/2024 20:52

Il be holding also till the end. Till the buyout!

[moneymunch] 28/1/2024 19:17

Always best to buy on the low and not sell on the low imho, but hope you do well wherever...Big news here could drop at anytime and I'll be holding Big for when it does...Tick Tock:-)

[kubera369] 28/1/2024 19:07

At the end of the day it's all about making money and with my experience here I rather gamble all in BiRD and if the share price here is still low as it is then all good Genflow is a winner but only when the FDA announce that Ageing is a disease and the NASH trials are still well over 12 months away.Cannot deal with the daily drip down of share price here We had no news since last year Aoril spike in share price until just recent and the share price again has dipped down It's crazy and I'm taking a calculated gamble and am certainly not going to get my wings clipped Good luck here and I may be back

[kubera369] 28/1/2024 19:01

Money take a view of the video I've posted Like I said I'm going by gut and let's see where we're at in 1 month;-)

[moneymunch] 28/1/2024 18:43

Lol...I'm going to be buying more Genflow on any drop, but good luck on wherever you invest, and hope you don't get your wings clipped!!! :-)))

[stark industries] 28/1/2024 17:26

Hey Kubera ...you have a art of stock picking and thanks for the heads up....I'm gonna be buying some BIRD next week... lol
Can't be in too many stocks but I like the look of BIRD...a Unicorn in the making for sure.
Thanks;))

[kubera369] 28/1/2024 17:05

I will be selling a good chunk of my shares here and taking a gamble to buy BIRD as mentioned I'm interested in GENFLOW but am going by my gut that the no new news flow will be released and with the thin trading and hardly any real market interest the shares will take a slide down again as there seems to be sellers Let's see if I'm right, and if BIRD goes to 15p whilst we are still sat at around this share price at Genflow - then I will again double my shares Best time to buy here will be when the FDA announce that Ageing is a disease Tick Tock We are 18 months away from NASH human trials so I say BIRD will be almost 30p Let's see

[kubera369] 28/1/2024 09:28

Sharing is caring fellow investors BlackBird interviewHTTps://www.proactiveinvestors.co.uk/companies/news/1033943/blackbird-bang-on-schedule-with-elevate-io-rollout-1033943.htmlWow!!!!BLACKBIRD is going to be a massive success Markets in the multiple billions.Will be buying a lot more this coming week at this low pricesApologies off topic

[kubera369] 28/1/2024 09:04

Whilst we are all sat here waiting I am going to recommend a fantastic share tip with you all if your interestedTICKER : BIRD (BLACKBIRD)last year I almost doubled my holdings in Genflow by buying bombed out winners and BIRD is an amazing opportunity imoGenflow has a knack get to.a point where there are hardly any trades happening and share price does nothing.It's all about volume and investors interest that moves share prices Don't miss out and have a great day

[moneymunch] 27/1/2024 11:25

Eric said that he’s expecting a crazy money buy out as soon as the FDA recognise ageing as a disease and he expects it soon, and that’s why he listed in both the UK and US to get the interest of the big pharma above all over companies who work in similar fields. He also said that something similar had happened to him before in another company and the warning signs are there for him once again. Holding tight!

[moneymunch] 27/1/2024 11:16

What’s the story?

The Food and Drug Administration (FDA) recognizes aging as a natural process of life, which some scientists are trying to change. There is a growing consensus among the scientific community that aging should be considered a disease.

Experts are urging the FDA to classify aging as a disease to make it easier to approve drugs and therapies that seek to slow down the effects of aging on the human body.

If the FDA agrees to recognize aging as a disease, researchers and drug companies could develop and gain approval for treatments that not only delay the aging process, but could potentially stunt the progression of accompanying conditions.

What is the scientific community saying?

The World Health Organization (WHO), a supporter of this measure, described aging as “...the impact of the accumulation of a wide variety of molecular and cellular damage over time,” which scientists say is a significant risk factor for other fatal conditions.

Supporting researchers say that while aging in and of itself is not an unnatural condition, the deterioration of the human body and its functions are symptoms of aging, just like that of a disease. Classifying aging as a disease would allow the medical community to directly fight the symptoms of aging to prevent another medical condition from developing.

David Sinclair, a geneticist at Harvard Medical School, argues that if we label aging differently, it will give the medical community a better chance at treating the health of the elderly and not just the diseases that accompany old age.

He said:

"Many of the most serious diseases today are a function of aging. Thus, identifying the molecular mechanisms and treatments of aging should be an urgent priority. Unless we address aging at its root cause, we're not going to continue our linear, upward progress toward longer and longer life spans."

[kubera369] 27/1/2024 09:16

Just need to wait now for the FDA to confirm that Ageing is a disease Tick Tock !

[moneymunch] 27/1/2024 08:54

Genflow Biosciences Plc 2023 Year in Review

2023 was a busy and productive year for Genflow Biosciences Plc (“Genflow) marked by significant advancements in our mission to pioneer novel therapeutics for a longer, healthier life. The groundbreaking gene therapies that we are working on alongside our co-collaborators are being engineered to target both the ageing process, and reduce and delay the onset of age-related diseases. Our mission remains to lower healthcare expenditures while easing the emotional and social challenges associated with an ageing population.

We’ve made numerous strategic moves this year as a part of our ongoing efforts to strengthen our company, financial and market position. Our balance sheet remains strong, and we are in a solid financial position. To comply with the updated requirements of the existing grant from the Wallonia region, and to be eligible for future grant funding, we undertook an internal debt re-organization without dilution. This puts us in a favorable financial position compared to many other biotechnology companies.

We diligently continue to pursue the research, development, and safe implementation of our two pivotal programs centered on NASH (Non-Alcoholic Steatohepatitis) and Werner Syndrome and have made significant progress this year.

NASH. We are pleased to report that our NASH program, which afflicts an estimated 35 million individuals worldwide and ranks among the leading causes of chronic liver disease with the urgent need for life-saving liver transplants, is progressing to plan. This program is advancing steadily, underscoring our firm commitment to combatting this pressing global health issue. In collaboration with Dr. Manlio Vinciguerra, (a Genflow Scientific Advisory Board member based at the University of Liverpool), are gaining a significantly deeper understanding of the biochemical changes that occur in the treatment of NASH using the centenarian SIRT6. This research has led to us clearly identifying the workings of our lead drug candidate, GF-1002 and its potential benefits for NASH patients. As a result, we have accumulated important data and filed a new patent application on this specific activity. Additionally, NASH clinical trials are expected to begin in Q1-Q2 2025 following dialogue and subsequent agreement with the European Medicine Agency.

Werner Syndrome.

Simultaneously, we are making progress targeting Werner Syndrome, an accelerated ageing disease. Here, our vision is clear: to enhance the quality of life for affected patients and expedite the path towards swift and successful first-in-human trials under orphan drug designation. Our lead compound GF-3001, is a topical delivery of SIRT6 to the skin.

Key Milestones

Q1 2023: Issued a shareholder update on the Company’s progress, highlighting our expanded intellectual property portfolio through a provisional patent application focusing on the ability to edit the SIRT6 gene, shown to play a role in longevity and age-related diseases as well as our solid cash position.

Q2 2023: Expanded our intellectual property portfolio through a provisional patent application focusing on the ability to edit the SIRT6 gene, shown to play a role in longevity and age-related diseases. If successful, the patent will represent a significant breakthrough in the field of gene editing, with potential implications for longevity and other forms of gene therapy;

Genflow started trading on the OTCQB Venture Market in the US under the ticker GENFF. This move aligns with our strategic emphasis on the US due to its significant advancements in longevity and our ongoing collaborations with US-based institutions;

The Company appointed Prof. Dr. Sven Francque on our Scientific Advisory Board. Prof. Francque is currently Chairman of the Department of Gastroenterology and Hepatology of the University Hospital Antwerp and Full Professor of Medicine at the Faculty of Medicine and Health Sciences of the University of Antwerp in Belgium. He has a longstanding interest and expertise in nonalcoholic fatty liver disease and conducted [basic] research focusing on steatosis. His research unit continues to study pathophysiological mechanisms of NASH. He also conducts clinical research, and his unit is a partner in several research consortia supported by the European Commission.

Q3 2023: Received positive comments from the Federal Agency for Medicines and Health Products (FAHMP) of Belgium regarding the design of our upcoming Phase I/II clinical trials of our lead drug candidate, GF-1002 with patients suffering from NASH. Following our encouraging results from in-vitro human cell and in-vivo rodent studies, the Agency concurred with Genflow’s proposal to commence clinical trials directly with NASH patients, thereby bypassing Phase I trials with healthy volunteers;

Appointed Harbor Access, a strategic Investor Relations firm with offices in the US and Canada to provide investor relations support and investor outreach.


Q4 2023: Appointed Capital Plus Partners Ltd (“CPP”) to act as Joint Broker, alongside Clear Capital Markets Limited. The addition of CPP is expected to bring additional expertise to the Company, strengthen our position and improve access to the capital;

Appointed Prof. Dr. Mary E. Rinella, Director, Metabolic and Fatty Liver Disease Department at the University of Chicago. She has investigated a broad range of topics within fatty liver disease, including the use of non-invasive measures to minimize the use of liver biopsy and the study of new therapies to treat fatty liver disease, since there is still no FDA approved treatment. Dr. Rinella has published nearly 150 peer-review articles in prestigious journals, such as Nature Reviews Gastroenterology & Hepatology, Gastroenterology, Hepatology, Journal of the American Medical Association (JAMA), The Lancet and others.

Heading into 2024, Genflow is well placed to take advantage of the recent resurgence of interest in the longevity sector. We continue to monitor opportunities, and to prioritize marketing efforts to expand our investor audience in North America and Europe. Our commitment to innovation and improving lives remains steadfast, as we navigate the opportunities and challenges that lie ahead. Together, we envision a future where our pioneering work redefines possibilities, bringing hope and transformative solutions to those who need it most.

Dr. Eric Leire
Founder and CEO
Genflow Biosciences Plc
January 25, 2024

[moneymunch] 27/1/2024 08:49

Updates

View organization page for Genflow Biosciences (LON:GENF) (OTCQB:GENFF)
Genflow Biosciences (LON:GENF) (OTCQB:GENFF)

1,455 followers
20h

Genflow Biosciences (LON:GENF) (OTCQB:GENFF) is excited to announce the release of its Annual 2023 Year in Review. This past year, we have achieved significant progress in our primary research areas in Non-Alcoholic Steatohepatitis (NASH) and Werner Syndrome.

Alongside these achievements, we have also made considerable strides in fortifying our corporate structure, enhancing our financial stability, and expanding our market presence to North America.

Read it here:

#longevity #NASH #Werner #SIRT6 #ageing #Genflow #GENF

[luckyabbeygale] 26/1/2024 12:38

There really is some idiots who just love to sell them and buy them back straight away to give the market makers free money.
This seems to be happening more and more.
It makes no sense at all.

[luckyabbeygale] 26/1/2024 12:31

Good to see that someone just had sellers regret and decieded to buy back the 39,551 shares sold.

[moneymunch] 26/1/2024 08:30

On and UP!!! Gla holders, all set for a great year ahead...in Eric we trust!!! :-)

[aberdeano] 26/1/2024 08:00

We are now at the start of a new Bull market for 2024. Once this share is more in the public domain it won’t wait for anyone.